• Source: SRT-2104

SRT-2104 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. The compound progressed to Phase II human trials for Type II diabetes before development was discontinued, however it continues to be widely used in animal research into the functions of SIRT1.




See also


SRT-1460
SRT-1720
SRT-2183
SRT-3025
STAC-9




References

Kata Kunci Pencarian:

• SRT-2104
• Sirtris Pharmaceuticals
• STAC-9
• Sirtuin
• SRT-3025
• ZF 8HP transmission
• System Support Program